Table 1.
Patients’ characteristics
| Characteristics | Transplant donor CMV-CTLs (n = 62) | Third-party CMV-CTLs (n = 31) | P value |
|---|---|---|---|
| Follow-up (median, d) | 1000 (146–2210) | 910 (154–2415) | 0.65 |
| Age (median, y, range) | 31.50 (7–59) | 37 (7–55) | 0.19 |
| Sex (M/F) | 32/30 | 21/10 | 0.18 |
| Disease type, n (%) | 0.89 | ||
| AML | 25 (40.32) | 13 (41.94) | |
| ALL | 22 (35.48) | 9 (29.03) | |
| MDS | 8 (12.90) | 4 (12.90) | |
| Others | 7 (11.29) | 5 (16.13) | |
| Transplant type (n, %) | <0.01 | ||
| HLA-matched SCT | 2 (3.22) | 2 (6.45) | |
| HLA-mismatched SCT | 60 (96.78) | 22 (70.97) | |
| Unrelated SCT | 0 (0.00) | 7 (22.58) | |
| Maximal acute GVHD before infusions (n, %) | 0.82 | ||
| 0-I | 37 (59.67) | 16 (51.61) | |
| II-IV | 25 (40.33) | 12 (38.71) | |
| CMV serological status of transplant donor (n, %) | <0.01 | ||
| Positive | 62 (100.00) | 18 (58.06) | |
| Negative | 0 (0.00) | 8 (25.80) | |
| Unkonwn | 0 (0.00) | 5 (16.12) | |
| CMV reactivation day post SCT (d, median) | 33 (17–49) | 29 (15–67) | 0.26 |
| CMV-CTLs infusion day post SCT (d, median) | 71 (51–158) | 59 (44–198) | 0.09 |
| CMV persistent time before infusion (d, median) | 26 (15–119) | 20 (15–134) | 0.23 |
| Median CMV titer before infusion (103/ml) | 7.00 (1.60–103.20) | 4.20 (1.10–77.00) | 0.08 |
| Peak CMV titer before infusion (103/ml) | 36.60 (4.70–1030) | 22.60 (2.70–680) | 0.20 |
| CMV disease before infusion (n, %) | 10 (16.10) | 3 (9.70) | 0.40 |
Abbreviations: M Male; F Female; AML Acute myeloid leukemia; ALL Acute lymphoblastic leukemia; MDS Myelodysplastic syndrome; SCT Stem cell transplantation; GVHD graft-versus-host disease; CMV Cytomegalovirus; CMV-CTLs, Cytomegalovirus-specific cytotoxic T lymphocytes